Monday, July 28, 2014
Inquirer Daily News

BioClinica, Novo Nordisk report growth

Area pharma companies BioClinica and Novo Nordisk both said this week they are growing in what they do best.

BioClinica, Novo Nordisk report growth

Area pharmaceutical companies BioClinica and Novo Nordisk both said this week they are growing in what they do best.

BioClinica, which is based in Newtown, Bucks County, is a contract research organization (CRO) which means it administers clinical trials all over the globe for drug companies.

BioClinica said revenues increased from $16.9 million to $19.1 million (an increase of 12.8 percent) as compared with the same period in 2011. Using GAAP formula, BioClinica said its profit rose from $924,000 to $1 million for the same period.

The link to the BioClinica press release and report is here.

Novo Nordisk is based in Denmark, but has a big operation in Princeton and is perhaps an outsized player in the huge space of diabetes care.

Reuters reported that Novo predicts full-year sales growth of 9 to 12 percent, versus the previous forecast range of 8 to 11 percent, using local currencies. Novo also predicted operating profits of 15 percent for the year.

The link to the Reuters story is here.

 

 

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected